EBEdwina Anne Brown

Edwina Anne Brown

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edwina Anne Brown has a total of 433 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recommendations for the management of frailty in chronic kidney disease: a consensus report

    by Philip Kam-Tao Li, Gordon Chun-Kau Chan, Mara McAdams-DeMarco, Stephanie Thompson, Marjolijn van Buren, Andrew C. Nixon, Jack Kit-Chung Ng, Ruth E. Hubbard, Sarbjit Vanita Jassal, Chia-Ter Chao, et al.

    Frailty is highly prevalent in patients with chronic kidney disease (CKD) and is associated with increased mortality, hospitalization and disability and with poorer quality of life. Despite its prognostic importance, substantial knowledge gaps remain with regard to the optimal tools for assessing frailty in CKD settings, the extent to which frailty can be reversed through targeted interventions, and how frailty should inform decision-making between conservative kidney management and kidney replacement therapy (KRT). This consensus report provides 63 consensus statements across four domains covering the assessment of frailty, interventions aimed at targeting the modifiable contributors to frailty in patients with CKD, considerations related to conservative kidney management and KRT, and the management of stage 5 CKD in the presence of frailty. Key recommendations include the need for routine frailty screening using multi-dimensional tools; the implementation of interventions to target physical activity with a focus on resistance training, adequate dietary protein intake, medication optimization and comprehensive geriatric assessment; a frailty-informed, person-centred framework for shared decision-making that emphasizes transparent communication, goal elicitation and cultural safety; and flexible KRT delivery — including less intensive dialysis schedules, assisted home dialysis and transplant eligibility assessment — guided by serial frailty measurement. The report concludes with priority research questions and a patient partner’s reflections on the co-production of consensus statements.


  • Evaluating Patterns and Outcomes in the Prescription of Incremental Peritoneal Dialysis in Support of Shared Decision Making

    by Jessica Selwood, Rishana Shuaib, Ted J. FitzGerald, Sally Punzalan, Gaetano Lucisano, Edwina A. Brown, Richard W. Corbett

    Key Points: Most people on incremental peritoneal dialysis did not require changes to their starting prescription within the first 12 months. Age, male sex, and lower serum albumin at dialysis start were associated with the timing of dialysis prescription increments. Low rates of transfer to hemodialysis and death rates confirmed the safety of incremental peritoneal dialysis regimens. Introduction: Incremental peritoneal dialysis (PD), where less than full-dose prescriptions are increased as residual kidney function declines, contributes to increased quality of life and reduced dialysis burden. Evidence supporting the safety of incremental regimens and informing patient expectations is limited. This study examined time to increment in dialysis prescriptions, PD modality transfer, transfer to hemodialysis, and mortality rates within a single center delivering incremental PD. Methods: Patients incident to PD and on incremental regimens were followed for changes in prescription, modality transfer, and death between January 1, 2012, and December 31, 2023. Multivariable Cox regression assessed factors associated with time to increment, and Kaplan–Meier methods with log-rank testing were used for time-to-event analyses. Results: The cohort included 527 patients. At 1 year, 64% (95% confidence interval [CI], 60% to 69%) remained on the same starting regimen, with 36% of people (95% CI, 31% to 41%) having not incremented by 2 years. Time to increment was shorter for younger age at PD start (per decade, hazard ratio [HR], 0.92; 95% CI, 0.85 to 0.99; P = 0.02), male sex (HR, 1.67; 95% CI, 1.29 to 2.16; P < 0.001), and lower serum albumin (HR, 0.96; 95% CI, 0.94 to 0.98; P < 0.001). PD modality transfer was driven by lifestyle, fluid overload, and uremic symptoms. Transfer to hemodialysis was associated with younger age ( P = 0.03) and diabetes mellitus ( P = 0.04), while time to hemodialysis transfer was correlated with lower albumin ( P = 0.01) and starting eGFR ( P = 0.006). Mortality rates were low at 0.11 events per person-year. Conclusion: Younger age, male sex, and lower albumin at dialysis start are associated with a shorter time to increment. Low rates of transfer to hemodialysis and death rates in this cohort support the safety of incremental PD prescribing. A simple clinical score was subsequently constructed and tested as a method of supporting shared decision making and informing patient expectations of treatment, but requires validation in future studies.


  • Moving Beyond Frailty Assessments in Kidney Transplantation of Older People

    by Amarpreet K. Thind, Melanie Dani, Edwina A. Brown

  • Open Access

    Peritoneal Dialysis Is the Best Modality for Old, Frail People

    by Jessica Selwood, Edwina A Brown

    An ageing population in the UK has seen an increased prevalence of chronic kidney disease (CKD), with a higher proportion of old, frail people requiring kidney replacement therapy. This article aims to explore why peritoneal dialysis (PD) may be the optimal dialysis modality for older people, considering factors such as frailty and cognitive impairment. PD offers considerable benefits over haemodialysis, including improved quality of life, benefits to cognition and higher treatment satisfaction. Assisted PD supports the maintenance of treatment for those with physical or cognitive impairments and helps to alleviate caregiver burden. Despite this, challenges such as treatment burden and peritonitis should be thoroughly considered. Overall, PD aligns well with the priorities of older people, emphasising quality of life and autonomy over survival. However, there needs to be improved funding and access to assisted PD programmes going forward to ensure PD is a viable treatment option.

  • Sex-Specific Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study

    by Rehab Albakr, Dhajanae Sylvertooth, Brian Bieber, Shilpanjali Jesudason, David W. Johnson, Hideki Kawanishi, Kosaku Nitta, Yong-Lim Kim, Talerngsak Kanjanabuch, Mihran Naljayan, et al.

    Sex differences may influence peritoneal dialysis (PD) outcomes for individuals with kidney failure and remain poorly understood. Understanding these differences is important in optimizing dialysis care and addressing disparities in treatment outcomes. We sought to explore association of sex with PD outcomes. Data from the international PD Outcomes and Practice Patterns Study across eight countries were used to examine sex differences in outcomes, including mortality, transfer to hemodialysis, the composite of both, peritonitis risks, and kidney transplantation. Cause-specific Cox regression models were used to assess the association between sex and each clinical outcome, adjusting for region, comorbidities, demographic, and treatment characteristics. Of 26,292 included individuals on PD, 43% were female, ranging from 34% in Japan to 51% in Thailand. Women (compared with men) had lower mortality (rate per 100 patient-years [PY100], 10.9 versus 11.3; adjusted hazard ratio [aHR] of mortality, 0.92 [95% confidence intervals (CIs), 0.86 to 0.99]), transfer to hemodialysis (PY100, 16.3 versus 17.9; aHR, 0.87 [95% CI, 0.83 to 0.92]), the composite of both (PY100, 27.2 versus 29.0; aHR, 0.89 [95% CI, 0.85 to 0.93]), and time to first observed peritonitis (PY100, 17.5 versus 18.7; aHR, 0.90 [95% CI, 0.84 to 0.95]), while transplant hazards were similar (PY100, 4.0 versus 4.0; aHR, 0.97 [95% CI, 0.87 to 1.08]). In subgroup and additional analyses, sex differences in outcomes were particularly apparent in South Korea, with a median time on PD of 6.4 years for women and 4.9 years for men, with South Korea women having lower hemodialysis transfer and transplant rates. Across all countries, diabetes substantially attenuated the lower risks of death and hemodialysis transfer in women. Women had significantly lower risks of gram-positive peritonitis (aHR, 0.73 [95% CI, 0.65 to 0.82]). Compared with men, women receiving PD have lower likelihoods of mortality, hemodialysis transfer, and peritonitis. Better understanding of these findings will help inform sex-specific strategies for managing PD while enhancing personalized care approaches in this patient population.


  • Advances in sorbent peritoneal dialysis technologies: A narrative review

    by Susan Bríd McGrath, Pauline Kosalka, Marjorie W Foo, Htay Htay, Edwina A Brown, Karin Gf Gerritsen, Olof Heimbürger, Arsh K Jain

    Sorbent peritoneal dialysis (SPD) removes a tidal volume of spent dialysate, passing it through sorbent layers before infusing replacement electrolytes and dextrose to regenerate dialysate. We examine the five devices using SPD in published literature, reviewing their design, dialysis clearance, and ultrafiltration (UF) capacity—Automated Wearable Artificial Kidney (AWAK), now called Viva Kompact since 2024, Carry Life System PD/Carry Life UF, Wearable Artificial Kidney (WEAKID), Vicenza Wearable Artificial Kidney (ViWAK), and Renart-PD. Carry Life devices and Viva Kompact have reported on human trials, WEAKID and Renart-PD on animal studies, while ViWAK has published in vitro data. All devices have published data on dialysis clearance capabilities. WEAKID and Carry Life PD achieved a high dialysate:plasma concentration gradient for small solutes. Viva Kompact and Renart-PD reported stable or lower serum concentrations of urea, creatinine, phosphate, and β2-microglogulin following treatments. ViWAK demonstrated removal of creatinine, B2 microglobulin, and angiogenin to <10% of pre-treatment levels. UF capacity remains unknown for many devices. In human trials, Carry Life UF has achieved 863 mL UF in a 5-h treatment with the addition of 20 g/h of glucose to 1.5% dextrose dialysate. Viva Kompact has demonstrated 877 mL UF in a 9-h treatment using 1.5% dextrose dialysate in an animal model, comparable to 10-h APD, with the addition of 6.6 g/h glucose. Both devices have demonstrated improved UF per gram of glucose used. The expected use of these devices varies greatly, from an adjunct to currently available treatments to a complete replacement for current modalities. Large-scale, human studies are needed to determine their role in the future of PD delivery.


  • Epidemiology of peritoneal dialysis exit site infections: Does sex play a role?

    by Hannah Beckwith, Lourelei Cepe, Sally Punzalan, Anan Ghazy, Gaetano Lucisano, Richard Corbett, Edwina A Brown

    Identifying risk factors that pre-dispose people on peritoneal dialysis (PD) to develop exit site infections (ESIs) may help improve prevention and treatment. Given the differences anatomically, hormonally and of the microbiota profile between males and females, we hypothesised that there is a difference in ESI incidence, outcomes, and the epidemiology of organism-specific ESI between males and females. This study was a retrospective case note review of all PD patients at our centre between 2012 and 2024. Of the 486 patients on PD, 202 (42%) were female and 273 positive swabs from 151 patients were identified (0.18 patient episodes/year). We found no statistically significant difference in the incidence of ESI between sexes in our cohort. Gram-positive organisms accounted for 126/273 (46.2%) of all ESI swabs, suggesting that current empiric antibiotic therapy potentially offers effective treatment for less than half of ESI only. We found significant morbidity from ESI: 39 (14%) patients developed peritonitis and 40 (15%) required catheter removal. Sex had no influence on ESI incidence, microbiology of infection or outcome.


  • Open Access

    Frailty Impact on Kidney Transplantation in Older People

    by Amarpreet K. Thind, Michelle Willicombe, Frank J.M.F. Dor, Lina Johansson, Nicola Thomas, Annabel Rule, Dawn Goodall, Shuli Levy, Sarah Brice, David Ospalla, et al.


  • Open Access

    Patient Perception of Dialysis Experience

    by Edwina A. Brown, Jessica Selwood

  • Open Access

    International Home Dialysis Consortium: Declaration Advocating for the Promotion of Home Dialysis Globally

    by Edwina A. Brown, Vivekanand Jha, Sunita Bavanandan, Christopher T. Chan, Simon Davies, Ana Figueirido, Adrian Liew, Magdalena Madero, Abdou Niang, Rajnish Mehrotra, et al.